Octave Strengthens Clinical Expertise in MS and Neurodegenerative Disease – Read the Release

Contact Us

Real-World Evidence of Tysabri (Natalizumab) Dose Interval Trends in People with Multiple Sclerosis from Administrative Claims Data

March 31, 2023inByCommentNo Comments
Click here

© 2025 Octave Bioscience, Inc | 1440 O’Brien Drive, Suite B, Menlo Park, CA 94025 

Connect with us